Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart C Gordon

Showing results (161-170 of 214) with videos related to

Pageof 22
Sort By:
Antiviral Research|June 11, 2013
Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokineticsEric Lawitz, Mark Sulkowski, Ira Jacobson, et al.
Journal of Hepatology|May 24, 2016
Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis BAnna S Lok, Calvin Q Pan, Steven-Huy B Han, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 20, 2012
Baseline characteristics and mortality among people in care for chronic viral hepatitis: the chronic hepatitis cohort studyAnne C Moorman, Stuart C Gordon, Loralee B Rupp, et al.
Hepatology (Baltimore, Md.)|January 28, 2017
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatmentFred Poordad, Franco Felizarta, Armen Asatryan, et al.
Gastroenterology|December 16, 2014
Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acidGideon M Hirschfield, Andrew Mason, Velimir Luketic, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 26, 2017
Factors Associated With Prevalence and Treatment of Primary Biliary Cholangitis in United States Health SystemsMei Lu, Jia Li, Irina V Haller, et al.
The Lancet. Gastroenterology & Hepatology|June 13, 2020
Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label studyEric Lawitz, Charles S Landis, Steven L Flamm, et al.
Virology|July 24, 2013
Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studiesRichard J O Barnard, John A Howe, Robert A Ogert, et al.
Hepatology (Baltimore, Md.)|June 22, 2010
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infectionAndrew J Muir, Mitchell L Shiffman, Atif Zaman, et al.
Journal of Viral Hepatitis|February 11, 2019
Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infectionEric Lawitz, Fred Poordad, Leah J Anderson, et al.
Pageof 22

Showing results (161-170 of 214) with videos related to

Sort By:
Pageof 22
Antiviral Research|June 11, 2013
Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokineticsEric Lawitz, Mark Sulkowski, Ira Jacobson, et al.
Journal of Hepatology|May 24, 2016
Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis BAnna S Lok, Calvin Q Pan, Steven-Huy B Han, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 20, 2012
Baseline characteristics and mortality among people in care for chronic viral hepatitis: the chronic hepatitis cohort studyAnne C Moorman, Stuart C Gordon, Loralee B Rupp, et al.
Hepatology (Baltimore, Md.)|January 28, 2017
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatmentFred Poordad, Franco Felizarta, Armen Asatryan, et al.
Gastroenterology|December 16, 2014
Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acidGideon M Hirschfield, Andrew Mason, Velimir Luketic, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 26, 2017
Factors Associated With Prevalence and Treatment of Primary Biliary Cholangitis in United States Health SystemsMei Lu, Jia Li, Irina V Haller, et al.
The Lancet. Gastroenterology & Hepatology|June 13, 2020
Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label studyEric Lawitz, Charles S Landis, Steven L Flamm, et al.
Virology|July 24, 2013
Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studiesRichard J O Barnard, John A Howe, Robert A Ogert, et al.
Hepatology (Baltimore, Md.)|June 22, 2010
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infectionAndrew J Muir, Mitchell L Shiffman, Atif Zaman, et al.
Journal of Viral Hepatitis|February 11, 2019
Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infectionEric Lawitz, Fred Poordad, Leah J Anderson, et al.
Pageof 22